Pharmaceutical company JOINN Laboratories (China) Co.,Ltd. (ASX: 603127) has announced its preliminary financial expectations for the first half of the year.

The firm projects its net profit attributable to shareholders will be in the range of 600 million to 900 million yuan, representing a substantial year-on-year increase of approximately 884.9% to 1377.4%.

Key Drivers of Performance

This impressive growth is primarily attributed to a favorable fair value change in biological assets during the reporting period.

The positive adjustment was driven by a dual effect: rising market prices for these assets coupled with their natural growth and appreciation.

Operational Context

Concurrently, the company's laboratory operations have maintained a stable and sound condition.

Despite a broader industry recovery, revenue growth for the period was modest.

The company noted that this limited top-line increase, along with a gross margin level still in recovery, is a lingering effect of the intense competition that characterized the industry in prior periods.